Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
1.
Clin Neuropharmacol ; 46(6): 205-208, 2023.
Article in English | MEDLINE | ID: mdl-37962306

ABSTRACT

OBJECTIVE: In this case report, we discuss the rare manifestation of prolonged neuromuscular blockade in a patient with history of small cell lung cancer and undiagnosed Lambert-Eaton myasthenic syndrome (LEMS) who had previously received succinylcholine for general anesthesia without incident but subsequently exhibited prolonged neuromuscular blockade during a laparoscopic procedure. We aimed to emphasize the importance of reversal agent safety and precision as well as vigilant perioperative and postoperative care. METHODS: We used the patient's electronic medical record, direct patient care experiences, and comprehensive literature review for this case report. RESULTS: Sugammadex was administered with mild improvement. Suspecting undiagnosed LEMS, neostigmine was administered, yielding satisfactory muscle strength and successful extubation. In retrospect, the patient reported history of weakness when lifting weights that improved upon exertion. CONCLUSIONS: Sugammadex is an efficient and effective agent for reversal of neuromuscular blockade. However, proper monitoring of the depth and recovery of blockade is imperative to when using sugammadex with optimal safety and precision in all patients. Perioperative care teams must remain vigilant with a high index of suspicion for neuromuscular junction pathology to properly plan perioperative care for patients at risk, especially those with small cell lung cancer who may have undiagnosed LEMS.


Subject(s)
Lambert-Eaton Myasthenic Syndrome , Lung Neoplasms , Neuromuscular Blockade , Small Cell Lung Carcinoma , Humans , Lambert-Eaton Myasthenic Syndrome/diagnosis , Lambert-Eaton Myasthenic Syndrome/drug therapy , Lambert-Eaton Myasthenic Syndrome/pathology , Lung Neoplasms/complications , Lung Neoplasms/surgery , Neuromuscular Blockade/methods , Small Cell Lung Carcinoma/complications , Small Cell Lung Carcinoma/surgery , Sugammadex
2.
J Neurophysiol ; 129(5): 1259-1277, 2023 05 01.
Article in English | MEDLINE | ID: mdl-37073966

ABSTRACT

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune-mediated neuromuscular disease thought to be caused by autoantibodies against P/Q-type voltage-gated calcium channels (VGCCs), which attack and reduce the number of VGCCs within transmitter release sites (active zones; AZs) at the neuromuscular junction (NMJ), resulting in neuromuscular weakness. However, patients with LEMS also have antibodies to other neuronal proteins, and about 15% of patients with LEMS are seronegative for antibodies against VGCCs. We hypothesized that a reduction in the number of P/Q-type VGCCs alone is not sufficient to explain LEMS effects on transmitter release. Here, we used a computational model to study a variety of LEMS-mediated effects on AZ organization and transmitter release constrained by electron microscopic, pharmacological, immunohistochemical, voltage imaging, and electrophysiological observations. We show that models of healthy AZs can be modified to predict the transmitter release and short-term facilitation characteristics of LEMS and that in addition to a decrease in the number of AZ VGCCs, disruption in the organization of AZ proteins, a reduction in AZ number, a reduction in the amount of synaptotagmin, and the compensatory expression of L-type channels outside the remaining AZs are important contributors to LEMS-mediated effects on transmitter release. Furthermore, our models predict that antibody-mediated removal of synaptotagmin in combination with disruption in AZ organization alone could mimic LEMS effects without the removal of VGCCs (a seronegative model). Overall, our results suggest that LEMS pathophysiology may be caused by a collection of pathological alterations to AZs at the NMJ, rather than by a simple loss of VGCCs.NEW & NOTEWORTHY We used a computational model of the active zone (AZ) in the mammalian neuromuscular junction to investigate Lambert-Eaton myasthenic syndrome (LEMS) pathophysiology. This model suggests that disruptions in presynaptic active zone organization and protein content (particularly synaptotagmin), beyond the simple removal of presynaptic calcium channels, play an important role in LEMS pathophysiology.


Subject(s)
Lambert-Eaton Myasthenic Syndrome , Animals , Humans , Lambert-Eaton Myasthenic Syndrome/pathology , Calcium Channels/metabolism , Neuromuscular Junction/metabolism , Neurons/metabolism , Calcium Channels, Q-Type , Synaptotagmins , Mammals/metabolism
3.
J Neurol ; 269(10): 5272-5282, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35779086

ABSTRACT

Paraneoplastic syndrome is a group of clinical symptoms that occur in the state of systemic malignant tumors. Paraneoplastic syndrome of the nervous system can affect any part of the central and peripheral nervous system and may also affect the eyes. In neuroophthalmology, paraneoplastic syndrome has a variety of manifestations that can affect both the afferent and efferent visual systems. The afferent system may involve the optic nerve, retina and uvea; the efferent system may involve eye movement, neuromuscular joints or involuntary eye movements and pupil abnormalities and may also have other neurological symptoms outside the visual system. This article discusses the clinical manifestations, pathological mechanisms, detection methods and treatment methods of paraneoplastic syndrome in neuroophthalmology. The performance of paraneoplastic syndrome is diverse, the diagnosis is difficult, and the treatment should be considered systematically. Differential diagnosis, optimal evaluation and management of these manifestations is not only the key to treatment but also a challenge.


Subject(s)
Lambert-Eaton Myasthenic Syndrome , Neoplasms , Paraneoplastic Syndromes , Humans , Immunotherapy , Lambert-Eaton Myasthenic Syndrome/pathology , Paraneoplastic Syndromes/complications , Paraneoplastic Syndromes/diagnosis
4.
Biomolecules ; 12(6)2022 05 24.
Article in English | MEDLINE | ID: mdl-35740866

ABSTRACT

The mouse neuromuscular junction (NMJ) has long been used as a model synapse for the study of neurotransmission in both healthy and disease states of the NMJ. Neurotransmission from these neuromuscular nerve terminals occurs at highly organized structures called active zones (AZs). Within AZs, the relationships between the voltage-gated calcium channels and docked synaptic vesicles govern the probability of acetylcholine release during single action potentials, and the short-term plasticity characteristics during short, high frequency trains of action potentials. Understanding these relationships is important not only for healthy synapses, but also to better understand the pathophysiology of neuromuscular diseases. In particular, we are interested in Lambert-Eaton myasthenic syndrome (LEMS), an autoimmune disorder in which neurotransmitter release from the NMJ decreases, leading to severe muscle weakness. In LEMS, the reduced neurotransmission is traditionally thought to be caused by the antibody-mediated removal of presynaptic voltage-gated calcium channels. However, recent experimental data and AZ computer simulations have predicted that a disruption in the normally highly organized active zone structure, and perhaps autoantibodies to other presynaptic proteins, contribute significantly to pathological effects in the active zone and the characteristics of chemical transmitters.


Subject(s)
Autoimmune Diseases , Lambert-Eaton Myasthenic Syndrome , Animals , Autoantibodies , Autoimmune Diseases/pathology , Calcium Channels , Lambert-Eaton Myasthenic Syndrome/pathology , Mice , Neuromuscular Junction/pathology
5.
Thorac Cancer ; 11(5): 1334-1338, 2020 05.
Article in English | MEDLINE | ID: mdl-32154996

ABSTRACT

Lambert-Eaton myasthenic syndrome (LEMS) is a rare disease characterized by involvement of the neuromuscular junction. Most cases have an underlying malignancy, especially small-cell lung cancer (SCLC), while adenocarcinoma is less common. Here, we report a rare case of metastatic lung adenocarcinoma complicated with LEMS. In this case, L858R mutation was detected in the 21st exon of the EGFR gene. First-line treatment with gefitinib was given, and the patient has survived for more than six years. Early diagnosis of LEMS and timely and effective treatment can result in a good prognosis. We also searched for "lung cancer", or "carcinoma of lung", or "adenocarcinoma of lung", or "Lambert-Eaton myasthenic syndrome" in PubMed until 1 December 2019. Seven cases of lung adenocarcinoma complicated with LEMS were found, most of which had a poor prognosis. KEY POINTS: This article reports a rare case of metastatic lung adenocarcinoma with EGFR mutation, complicated with LEMS. Gefitinib was given as first-line treatment, and resulted in a good prognosis.


Subject(s)
Adenocarcinoma of Lung/secondary , Antineoplastic Agents/therapeutic use , Gefitinib/therapeutic use , Lambert-Eaton Myasthenic Syndrome/drug therapy , Lung Neoplasms/pathology , Humans , Lambert-Eaton Myasthenic Syndrome/etiology , Lambert-Eaton Myasthenic Syndrome/pathology , Male , Middle Aged , Prognosis
6.
Ann Thorac Surg ; 109(5): e347-e348, 2020 05.
Article in English | MEDLINE | ID: mdl-31586614

ABSTRACT

Thymic small cell cancer is a very rare type of thymic epithelial tumor. Lambert-Eaton myasthenic syndrome is a rare paraneoplastic syndrome associated with thymic epithelial tumors. We report an extremely rare case of Lambert-Eaton myasthenic syndrome associated with thymic small cell carcinoma. A 71-year-old man was referred to our institution for a mediastinal tumor and a 2-month history of ptosis, fatigue, and gait disorder. Based on radiologic findings thymoma associated with Lambert-Eaton myasthenic syndrome was diagnosed, and extended thymectomy was performed. After surgery the patient's symptoms had not improved. Anticholinesterase treatment alleviated his symptoms.


Subject(s)
Carcinoma, Small Cell/diagnosis , Lambert-Eaton Myasthenic Syndrome/diagnosis , Thymus Neoplasms/diagnosis , Aged , Carcinoma, Small Cell/pathology , Carcinoma, Small Cell/surgery , Cholinesterase Inhibitors/therapeutic use , Combined Modality Therapy , Electromyography , Humans , Lambert-Eaton Myasthenic Syndrome/pathology , Lambert-Eaton Myasthenic Syndrome/surgery , Magnetic Resonance Imaging , Male , Neurologic Examination , Postoperative Care , Rare Diseases , Thymectomy , Thymus Gland/pathology , Thymus Neoplasms/pathology , Thymus Neoplasms/surgery , Tomography, X-Ray Computed
7.
Brain ; 142(8): 2253-2264, 2019 08 01.
Article in English | MEDLINE | ID: mdl-31236596

ABSTRACT

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease of the neuromuscular junction caused by autoantibodies binding to P/Q-type voltage-gated calcium channels. Breakdown of the blood-brain barrier and diffusion of cerebellar granule/Purkinje cell-reactive autoantibodies into the CNS are critical for the pathogenesis of paraneoplastic cerebellar degeneration (PCD) with Lambert-Eaton myasthenic syndrome. We recently found evidence that glucose-regulated protein 78 (GRP78) autoantibodies in the plasma of patients with neuromyelitis optica promote the CNS access of AQP4 autoantibodies. In the present study, we investigated whether the GRP78 autoantibodies in PCD-LEMS IgG boost the brain uptake of cerebellar cell-reactive antibodies across the blood-brain barrier and facilitate cerebellar dysfunction. We first evaluated the effects of purified IgG from PCD-LEMS or PCD patients on the blood-brain barrier function in human brain microvascular endothelial cells using a high content imaging system with nuclear factor κB p65 and intracellular adhesion molecule 1 (ICAM1) immunostaining. Next, we identified GRP78 autoantibodies causing blood-brain barrier permeability in PCD-LEMS IgG by co-immunoprecipitation and the living cell-based antibody binding assays. Exposure of brain microvascular endothelial cells to IgG from PCD-LEMS patients induced nuclear factor κB p65 nuclear translocation, ICAM1 upregulation, reduced claudin-5 expression, increased permeability and increased autocrine IL-1ß and IL-8 secretion; the IgG from patients with Lambert-Eaton myasthenic syndrome did not have these effects. We detected GRP78 autoantibodies in the IgG of LEMS-PCD (83.3%, n = 18), but observed fewer in patients with LEMS (6.6%, n = 15) and none were observed in the control subjects (n = 8). The depletion of GRP78 autoantibodies reduced the biological effect of LEMS-PCD IgG on brain microvascular endothelial cells. These findings suggest that GRP78 autoantibodies play a role beyond neuromyelitis optica and that they have direct implications in the phenotypic differences between PCD-LEMS and LEMS.


Subject(s)
Autoantibodies/immunology , Blood-Brain Barrier/pathology , Heat-Shock Proteins/immunology , Lambert-Eaton Myasthenic Syndrome/immunology , Paraneoplastic Cerebellar Degeneration/immunology , Aged , Aged, 80 and over , Autoantigens/immunology , Endoplasmic Reticulum Chaperone BiP , Female , Humans , Lambert-Eaton Myasthenic Syndrome/pathology , Lung Neoplasms/immunology , Male , Middle Aged , Paraneoplastic Cerebellar Degeneration/pathology , Small Cell Lung Carcinoma/immunology
8.
Radiology ; 290(1): 264-269, 2019 01.
Article in English | MEDLINE | ID: mdl-30571477

ABSTRACT

History A 29-year-old woman presented with a 6-month history of progressive general fatigue, fluctuating limb weakness, and difficulty climbing stairs. She initially experienced occasional episodes of transient diplopia that developed while reading in the evening. She subsequently started to experience dry eyes and mouth, difficulty chewing, and mild dysphagia that worsened throughout the day. Her medical history included hypothyroidism from Hashimoto thyroiditis and pneumonia with left pleural effusion. She had no smoking history, and her body mass index was normal (23.8 kg/m2). No medication use was reported at admission. Physical examination revealed mild bilateral ptosis, reduced muscle tone and strength that worsened in proximal leg muscles, and decreased deep tendon reflexes. An edrophonium test revealed improvement in muscle strength and eyelid ptosis. Repetitive nerve stimulation revealed low amplitude of compound muscle action potential at rest (0.21 mV), with a marked increase (700%; normal increase, <60%) at high-rate stimulation (50 Hz). Laboratory work-up was unremarkable except for detection of acetylcholine receptor antibodies in the serum (21.30 nmol/L) and P/Q-type voltage-gated calcium channel antibodies (220 pmol/L). Recent MRI of the brain and spine at an outside hospital showed no abnormal findings. At admission, the patient underwent CT of the chest, abdomen, and pelvis followed by thoracic MRI to further evaluate CT findings.


Subject(s)
Lambert-Eaton Myasthenic Syndrome , Myasthenia Gravis , Thymoma , Thymus Gland , Thymus Neoplasms , Adult , Female , Humans , Lambert-Eaton Myasthenic Syndrome/diagnosis , Lambert-Eaton Myasthenic Syndrome/pathology , Magnetic Resonance Imaging , Myasthenia Gravis/diagnosis , Myasthenia Gravis/pathology , Photomicrography , Thymoma/diagnosis , Thymoma/pathology , Thymus Gland/diagnostic imaging , Thymus Gland/pathology , Thymus Neoplasms/diagnosis , Thymus Neoplasms/pathology , Tomography, X-Ray Computed
9.
Semin Neurol ; 38(3): 344-354, 2018 06.
Article in English | MEDLINE | ID: mdl-30011414

ABSTRACT

Autoimmune myasthenic syndromes are antibody-mediated disorders of the neuromuscular junction. Common antigenic targets are the acetylcholine receptor or muscle specific kinase (MuSK) in myasthenia gravis (MG) and the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. There is evidence that antibodies directed against other antigens such as low-density lipoprotein receptor-related protein 4 (LRP4) are also involved in MG. The mechanisms by which various antibodies exert their pathogenic effect depend on the IgG subclass and also the epitope location on the antigens. These mechanisms are partly heterogeneous and include antigen degradation, complement activation, direct functional blocking, or disruption of protein-protein interactions. The neuromuscular junction is characterized by a structural and functional plasticity that is able to compensate for some of the neuromuscular junction defects. Here, we discuss the underlying pathogenic mechanisms of the different autoantibodies and correlate them with phenotypic features. The understanding of these elements should help guide the clinical management of patients with autoimmune myasthenic syndromes.


Subject(s)
Autoantibodies/immunology , Lambert-Eaton Myasthenic Syndrome/immunology , Lambert-Eaton Myasthenic Syndrome/pathology , Neuromuscular Junction/immunology , Humans , Immunoglobulin G/immunology , Muscle Weakness/immunology , Muscle Weakness/pathology , Myasthenia Gravis/immunology , Myasthenia Gravis/pathology
10.
Cir Cir ; 86(1): 79-83, 2018.
Article in Spanish | MEDLINE | ID: mdl-29681644

ABSTRACT

Background: Neurological paraneoplastic syndromes are rare, occur in 0.01% of all cancer patients; like part of them, the Lambert-Eaton syndrome is an autoimmune presynaptic disorder of neuromuscular transmission characterized by muscle weakness and neurovegetative dysfunction, and often associated with small cell lung cancer. Case report: A 72 years old female with a family history of lung cancer and leukemia, with 7 months of dry cough and 3 months with waist and pelvic muscle weakness, oropharyngeal dysphagia, dry mouth, chronic constipation and weight loss of 10 kg. Physical examination: patient prostrated; clinical muscle examination: pelvic muscles waist -3/5 and -4/5 the rest; diminished reflexes. Laboratory normal parathormone and hypercalcemia. With electrophysiological study and positive anti-voltage-gated calcium channel antibodies, confirming Lambert-Eaton syndrome and imaging studies with neoplastic condition in brain, liver and kidney, with unspecified primary origin.


Antecedentes: Los síndromes paraneoplásicos neurológicos son poco frecuentes; se presentan en el 0.01% de todos los pacientes con cáncer. Uno de ellos es el síndrome de Lambert-Eaton, correspondiendo a un trastorno presináptico autoinmunitario de transmisión neuromuscular caracterizado por debilidad muscular y disfunción neurovegetativa, y asociado con frecuencia al carcinoma microcítico de pulmón. Caso clínico: Mujer de 72 años, con antecedentes heredofamiliares de cáncer de pulmón y leucemia, con tos seca de 7 meses, 3 meses con debilidad de los músculos de cintura pélvica, disfagia al inicio de la deglución, xerostomía, estreñimiento crónico y pérdida de peso de 10 kg. A la exploración física: paciente postrada; examen clínico muscular: músculos de cintura pélvica en −3/5, resto en −4/5; reflejos disminuidos. Pruebas de laboratorio indicando hipercalcemia y paratohormona normal. Estudio electrofisiológico y anticuerpos anticanales de calcio positivos, demostrando síndrome de Lamber-Eaton, y estudios de imagen con afectación neoplásica en cerebro, hígado y riñón, sin lograr especificar el origen primario.


Subject(s)
Lambert-Eaton Myasthenic Syndrome/etiology , Neoplasms, Unknown Primary/complications , Aged , Autoantibodies/blood , Autoantibodies/immunology , Autoantigens/immunology , Brain/pathology , Calcium Channels/immunology , Central Nervous System Neoplasms/secondary , Electromyography , Female , Gliosis/pathology , Humans , Kidney Neoplasms/secondary , Lambert-Eaton Myasthenic Syndrome/diagnosis , Lambert-Eaton Myasthenic Syndrome/pathology , Lambert-Eaton Myasthenic Syndrome/physiopathology , Liver Neoplasms/secondary , Magnetic Resonance Imaging , Muscular Atrophy/etiology , Tomography, X-Ray Computed , White Matter/pathology
11.
Ann N Y Acad Sci ; 1413(1): 119-125, 2018 02.
Article in English | MEDLINE | ID: mdl-29377152

ABSTRACT

We report a severe defect of neuromuscular transmission in a consanguineous patient with a homozygous variant in the laminin α5 subunit gene (LAMA5). The variant c.8046C > T (p.Arg2659Trp) is rare and has a predicted deleterious effect. The affected individual, who also carries a rare homozygous sequence variant in LAMA1, had normal cognitive function, but magnetic resonance brain imaging showed mild volume loss and periventricular T2 prolongation. Repetitive nerve stimulation at 2 Hz showed 50% decrement of compound muscle action potential amplitudes but 250% facilitation immediately after exercise, similar to that seen in Lambert-Eaton myasthenic syndrome. Endplate studies demonstrated a profound reduction of the endplate potential quantal content but normal amplitudes of miniature endplate potentials. Electron microscopy showed endplates with increased postsynaptic folding that were denuded or only partially occupied by small nerve terminals. Expression studies revealed that p.Arg2659Trp caused decreased binding of laminin α5 to SV2A and impaired laminin-521 cell adhesion and cell projection support in primary neuronal cultures. In summary, this report describing severe neuromuscular transmission failure in a patient with a LAMA5 mutation expands the list of phenotypes associated with defects in genes encoding α-laminins.


Subject(s)
Lambert-Eaton Myasthenic Syndrome/genetics , Lambert-Eaton Myasthenic Syndrome/pathology , Laminin/genetics , Myasthenic Syndromes, Congenital/genetics , Myasthenic Syndromes, Congenital/pathology , Synaptic Transmission/physiology , Adult , Female , Humans , Motor Endplate/physiology
12.
Ann N Y Acad Sci ; 1412(1): 73-81, 2018 01.
Article in English | MEDLINE | ID: mdl-29125190

ABSTRACT

Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder caused by antibodies directed against the voltage-gated calcium channels that provide the calcium ion flux that triggers acetylcholine release at the neuromuscular junction. To study the pathophysiology of LEMS and test candidate therapeutic strategies, a passive-transfer animal model has been developed in mice, which can be created by daily intraperitoneal injections of LEMS patient serum or IgG into mice for 2-4 weeks. Results from studies of the mouse neuromuscular junction have revealed that each synapse has hundreds of transmitter release sites but that the probability for release at each one is likely to be low. LEMS further reduces this low probability such that transmission is no longer effective at triggering a muscle contraction. The LEMS-mediated attack reduces the number of presynaptic calcium channels, disorganizes transmitter release sites, and results in the homeostatic upregulation of other calcium channel types. Symptomatic treatment is focused on increasing the probability of release from dysfunctional release sites. Current treatment uses the potassium channel blocker 3,4-diaminopyridine (DAP) to broaden the presynaptic action potential, providing more time for calcium channels to open. Current research is focused on testing new calcium channel gating modifiers that work synergistically with DAP.


Subject(s)
Lambert-Eaton Myasthenic Syndrome/etiology , Animals , Autoantigens , Carcinoma, Small Cell/etiology , Disease Models, Animal , Humans , Immunization, Passive , Lambert-Eaton Myasthenic Syndrome/pathology , Lambert-Eaton Myasthenic Syndrome/therapy , Lung Neoplasms/etiology , Mice , Neuromuscular Junction/pathology , Neuromuscular Junction/physiopathology , Neurotransmitter Agents/physiology
13.
J Neurol ; 264(9): 1854-1863, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28608304

ABSTRACT

Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular junction disorder that is related to the loss of functional P/Q-type voltage-gated calcium channels (VGCCs) on presynaptic nerve terminals. Up to 60% of cases occur as a paraneoplastic disorder (SCLC-LEMS), most commonly in association with small cell lung cancer. The remaining cases have an idiopathic non-tumor etiology but are associated with underlying autoimmune disease (NT-LEMS). Patients with LEMS invariably experience progressive proximal muscle weakness, often accompanied by general fatigue and autonomic symptoms. Some LEMS clinical symptoms overlap with those of other myasthenic syndromes, most commonly myasthenia gravis, which can contribute to misdiagnosis or delayed diagnosis. Prognosis is related to the presence of cancer or autoimmune disease and the severity/distribution of muscle weakness. Cause of death in patients with SCLC-LEMS is typically tumor progression, whereas NT-LEMS does not reduce life expectancy. LEMS diagnosis is supported by a threefold approach: clinical features, electromyography, and anti-VGCC antibody serology. LEMS is a clinically important early indicator of possible cancer; therefore, a LEMS diagnosis should immediately prompt rigorous oncological screening and surveillance. Symptomatic treatment of LEMS typically involves medications that improve neurotransmission (e.g., the potassium channel blocker amifampridine [3,4-diaminopyridine]), with addition of immunosuppressants/modulators (e.g., prednisone plus azathioprine) in individuals with persistent symptoms. Where a tumor is identified, oncological treatment should take priority. It should be remembered, however, that LEMS has a significant impact on a patient's quality of life and ability to perform daily activities, and therefore warrants timely diagnosis and appropriate treatment in and of itself.


Subject(s)
Lambert-Eaton Myasthenic Syndrome/complications , Lung Neoplasms/complications , Small Cell Lung Carcinoma/complications , Calcium Channels/genetics , Humans , Lambert-Eaton Myasthenic Syndrome/epidemiology , Lambert-Eaton Myasthenic Syndrome/genetics , Lambert-Eaton Myasthenic Syndrome/pathology , Lung Neoplasms/epidemiology , Quality of Life , Risk Factors , Small Cell Lung Carcinoma/epidemiology
14.
Muscle Nerve ; 56(2): 253-257, 2017 08.
Article in English | MEDLINE | ID: mdl-27935068

ABSTRACT

INTRODUCTION: We analyzed jitter recordings made with concentric needle electrode (CNE) single-fiber electromyography (SFEMG) in Lambert-Eaton myasthenia (LEM). METHODS: Fifteen subjects diagnosed with LEM were studied using CNE-SFEMG in the extensor digitorum (ED) and tibialis anterior (TA) muscles. CNE-SFEMG in the ED and TA was also used to evaluate 12 and 10 healthy controls (HCs), respectively. RESULTS: Ten men and 5 women were diagnosed with LEM based on an increase of 100% in compound muscle action potential amplitude during 50 Hz repetitive nerve stimulation. All patients exhibited markedly greater jitter in the ED (88.8 ± 23.2 µs) and TA (92.2 ± 30.2 µs) than HCs (28.3 ± 3.4 µs and 30.9 ± 5.1 µs, respectively). CONCLUSIONS: CNE-SFEMG is sensitive for discovering abnormalities in neuromuscular transmission in LEM. Muscle Nerve 56: 253-257, 2017.


Subject(s)
Lambert-Eaton Myasthenic Syndrome/pathology , Muscle Fibers, Skeletal/physiology , Action Potentials/physiology , Adult , Aged , Electric Stimulation , Electrodes , Electromyography , Fatigue/etiology , Female , Humans , Immunoglobulins, Intravenous/therapeutic use , Lambert-Eaton Myasthenic Syndrome/complications , Lambert-Eaton Myasthenic Syndrome/drug therapy , Male , Middle Aged , Muscle Weakness/etiology , Neural Conduction/physiology , Reflex/physiology , Retrospective Studies , Statistics, Nonparametric
15.
Matrix Biol ; 57-58: 86-105, 2017 01.
Article in English | MEDLINE | ID: mdl-27614294

ABSTRACT

The synapse between motor neurons and skeletal muscle is known as the neuromuscular junction (NMJ). Proper alignment of presynaptic and post-synaptic structures of motor neurons and muscle fibers, respectively, is essential for efficient motor control of skeletal muscles. The synaptic cleft between these two cells is filled with basal lamina. Laminins are heterotrimer extracellular matrix molecules that are key members of the basal lamina. Laminin α4, α5, and ß2 chains specifically localize to NMJs, and these laminin isoforms play a critical role in maintenance of NMJs and organization of synaptic vesicle release sites known as active zones. These individual laminin chains exert their role in organizing NMJs by binding to their receptors including integrins, dystroglycan, and voltage-gated calcium channels (VGCCs). Disruption of these laminins or the laminin-receptor interaction occurs in neuromuscular diseases including Pierson syndrome and Lambert-Eaton myasthenic syndrome (LEMS). Interventions to maintain proper level of laminins and their receptor interactions may be insightful in treating neuromuscular diseases and aging related degeneration of NMJs.


Subject(s)
Abnormalities, Multiple/genetics , Eye Abnormalities/genetics , Lambert-Eaton Myasthenic Syndrome/genetics , Laminin/genetics , Nephrotic Syndrome/genetics , Pupil Disorders/genetics , Abnormalities, Multiple/metabolism , Abnormalities, Multiple/pathology , Animals , Basement Membrane/metabolism , Basement Membrane/pathology , Calcium Channels/genetics , Calcium Channels/metabolism , Dystroglycans/genetics , Dystroglycans/metabolism , Eye Abnormalities/metabolism , Eye Abnormalities/pathology , Gene Expression , Humans , Integrins/genetics , Integrins/metabolism , Lambert-Eaton Myasthenic Syndrome/metabolism , Lambert-Eaton Myasthenic Syndrome/pathology , Laminin/metabolism , Motor Neurons/metabolism , Motor Neurons/pathology , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Myasthenic Syndromes, Congenital , Nephrotic Syndrome/metabolism , Nephrotic Syndrome/pathology , Neuromuscular Junction/metabolism , Neuromuscular Junction/pathology , Protein Binding , Pupil Disorders/metabolism , Pupil Disorders/pathology , Synaptic Vesicles/metabolism , Synaptic Vesicles/pathology
16.
Neuromuscul Disord ; 26(12): 880-884, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27816328

ABSTRACT

Tubular aggregates are accumulations of densely packed tubules in muscle fibers, occurring in distinct hereditary and acquired disorders. We present a patient with tubular aggregates and autoimmune Lambert-Eaton myasthenic syndrome. Initially, he showed mild proximal weakness, borderline decrement on 3 Hz stimulation, and slightly elevated creatine kinase. Muscle biopsy revealed tubular aggregates in type II fibers. Due to a good response to pyridostigmine, a limb-girdle myasthenia with tubular aggregates was suspected, but genetic analyses of GFPT1, DPGAT1, and ALG2 were normal. Two years later, the patient presented with progressive weakness and autonomic dysfunction. 17% decrement on 3 Hz stimulation and 100% increment after brief exercise were revealed. Autoantibodies to voltage-gated calcium-channels confirmed the diagnosis of Lambert-Eaton myasthenic syndrome. Steroids, azathioprine, and 3,4-diaminopyridine significantly improved symptoms. No tumor was found during follow-up. This is the first report about tubular aggregates associated with an acquired myasthenic syndrome. Our findings are important because of the therapeutic implications.


Subject(s)
Lambert-Eaton Myasthenic Syndrome/diagnosis , Lambert-Eaton Myasthenic Syndrome/pathology , Muscle, Skeletal/pathology , Adult , Diagnosis, Differential , Exercise/physiology , Humans , Lambert-Eaton Myasthenic Syndrome/drug therapy , Lambert-Eaton Myasthenic Syndrome/genetics , Male , Muscle, Skeletal/physiopathology
18.
Semin Neurol ; 35(4): 340-6, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26502758

ABSTRACT

Lambert-Eaton myasthenic syndrome (LEMS) and botulism are acquired presynaptic nerve terminal disorders of the neuromuscular junction. Lambert-Eaton myasthenic syndrome is an idiopathic or paraneoplastic autoimmune syndrome in which autoantibodies of the P/Q-type voltage-gated calcium channel play a role in decreasing the release of acetylcholine, resulting in clinical symptoms of skeletal muscle weakness, diminished reflexes, and autonomic symptoms. Paraneoplastic LEMS is most often associated with small cell lung cancer. Diagnosis is confirmed by positive serologic testing and electrophysiological studies, which display characteristic features of low compound muscle action potentials, a decrement at 3Hz repetitive nerve stimulation, and facilitation with exercise or high-frequency repetitive stimulation. Treatment involves cancer monitoring and treatment, 3,4-diaminopyridine, immunosuppressive medications, and acetylcholinesterase inhibitors. Botulism is another presynaptic disorder of neuromuscular transmission. Clinical features classically involve cranial and bulbar palsies followed by descending weakness of the limbs, respiratory failure, and autonomic dysfunction. Electrodiagnostic testing is important in the evaluation and diagnosis. Treatment is supportive, and administration of antitoxin is beneficial in selected cases.


Subject(s)
Botulism , Disease Management , Lambert-Eaton Myasthenic Syndrome , Presynaptic Terminals/pathology , Autoantibodies/immunology , Botulism/diagnosis , Botulism/pathology , Botulism/therapy , Female , Humans , Infant , Lambert-Eaton Myasthenic Syndrome/diagnosis , Lambert-Eaton Myasthenic Syndrome/pathology , Lambert-Eaton Myasthenic Syndrome/therapy , Male , Middle Aged
19.
Biochim Biophys Acta ; 1852(4): 651-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25486268

ABSTRACT

Disorders affecting the presynaptic, synaptic, and postsynaptic portions of the neuromuscular junction arise from various mechanisms in children and adults, including acquired autoimmune or toxic processes as well as genetic mutations. Disorders include autoimmune myasthenia gravis associated with acetylcholine receptor, muscle specific kinase or Lrp4 antibodies, Lambert-Eaton myasthenic syndrome, nerve terminal hyperexcitability syndromes, Guillain Barré syndrome, botulism, organophosphate poisoning and a number of congenital myasthenic syndromes. This review focuses on the various molecular and pathophysiological mechanisms of these disorders, characterization of which has been crucial to the development of treatment strategies specific for each pathogenic mechanism. In the future, further understanding of the underlying processes may lead to more effective and targeted therapies of these disorders. This article is part of a Special Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.


Subject(s)
Botulism , Guillain-Barre Syndrome , Lambert-Eaton Myasthenic Syndrome , Myasthenia Gravis , Organophosphate Poisoning , Adolescent , Adult , Autoantibodies/immunology , Autoantibodies/metabolism , Botulism/genetics , Botulism/immunology , Botulism/metabolism , Botulism/pathology , Child , Child, Preschool , Guillain-Barre Syndrome/genetics , Guillain-Barre Syndrome/immunology , Guillain-Barre Syndrome/metabolism , Guillain-Barre Syndrome/pathology , Humans , LDL-Receptor Related Proteins/genetics , LDL-Receptor Related Proteins/immunology , LDL-Receptor Related Proteins/metabolism , Lambert-Eaton Myasthenic Syndrome/genetics , Lambert-Eaton Myasthenic Syndrome/immunology , Lambert-Eaton Myasthenic Syndrome/metabolism , Lambert-Eaton Myasthenic Syndrome/pathology , Myasthenia Gravis/genetics , Myasthenia Gravis/immunology , Myasthenia Gravis/metabolism , Myasthenia Gravis/pathology , Neuromuscular Junction/genetics , Neuromuscular Junction/immunology , Neuromuscular Junction/metabolism , Neuromuscular Junction/pathology , Organophosphate Poisoning/genetics , Organophosphate Poisoning/immunology , Organophosphate Poisoning/metabolism , Organophosphate Poisoning/pathology , Receptors, Cholinergic/genetics , Receptors, Cholinergic/immunology , Receptors, Cholinergic/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...